<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H5BE78A5ACCA0437D99AA0DBBDE060873" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4692 IH: Increasing Prescription Drug Competition Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-07-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4692</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230717">July 17, 2023</action-date><action-desc><sponsor name-id="S001208">Ms. Slotkin</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to prevent the use of patents, trade secrets, or other intellectual property to inhibit competition.</official-title></form><legis-body id="H0A41EFEED8D94EE189880A06218B7525" style="OLC"><section section-type="section-one" id="H84023547FCAC4E77A2DC4FA5B249CDC5"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Increasing Prescription Drug Competition Act</short-title></quote>.</text></section><section id="HFDFC3F664879424ABC78DDD94724DD09"><enum>2.</enum><header>Preventing the use of patents, trade secrets, or other intellectual property on risk evaluation and mitigation strategies to inhibit competition</header><text display-inline="no-display-inline">Section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HD00AEABF154F45E89E4FB25FF592C1D6"><subsection id="H11CB3CDA4EAE479B9D7FEFD6C40A69B2"><enum>(n)</enum><header>Additional requirements</header><paragraph id="H84E488E06EDD40ABA112C0931DA035E2"><enum>(1)</enum><header>Patents claiming REMS</header><text>If an application under subsection (b)(2) or (j) of section 505 includes a certification under subsection (b)(2)(A) or (j)(2)(A)(vii) of section 505 with respect to a patent that claims an aspect of the elements to assure safe use of a risk evaluation and mitigation strategy requirements under subsection (f) for the applicable listed drug, such certification shall have no effect on the effective date of the approval of the application, notwithstanding subparagraphs (B) and (C) of section 505(c)(3) and clauses (ii) and (iii) of section 505(j)(5)(B). </text></paragraph><paragraph id="H42EB8303632A4A6787DBC0BD778D14F5"><enum>(2)</enum><header>Damages</header><text>In the event that the sponsor of another application under section 505 of this Act or section 351 of the Public Health Service Act infringes a patent, trade secret, or any other intellectual property held by the sponsor or holder to comply with risk evaluation and mitigation strategy requirements under this section, the sponsor or holder of the approved application shall not seek, or claim entitlement to, any remedy other than damages arising from the infringement. </text></paragraph><paragraph id="HAC0E2EBBFDD14CC0A45A4E79D2689551"><enum>(3)</enum><header>Clarifications</header><text>Nothing in this section shall be construed as—</text><subparagraph id="H76FDD4A58BD648D3B761E66237B23159"><enum>(A)</enum><text>prohibiting the sponsor or holder of an approved application from allowing the sponsor of another application under section 505 of this Act or section 351 of the Public Health Service Act to use the patent, trade secret, or any other intellectual property other than as described in this subsection;</text></subparagraph><subparagraph id="H35982BB5FFCF4024977FFA2F7EA7E75C"><enum>(B)</enum><text>preventing a sponsor of an application under section 505 of this Act or section 351 of the Public Health Service Act from using a different, comparable aspect of the elements to assure safe use as authorized under this section;</text></subparagraph><subparagraph id="HFF449A228DF54E5C8ED1B7B141060D38"><enum>(C)</enum><text>in any way negating the applicability of a risk evaluation and mitigation strategy with elements to assure safe use, as otherwise required under this section; or</text></subparagraph><subparagraph id="HD6FA07E0CCF94C70952E54B331A56629"><enum>(D)</enum><text>limiting the application of any provision of the antitrust laws (as defined in subsection (a) of the first section of the Clayton Act (<external-xref legal-doc="usc" parsable-cite="usc/15/12">15 U.S.C. 12(a)</external-xref>).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

